

Sample content

# Ovarian Cancer

Disease Landscape & Forecast

# About Disease Landscape & Forecast

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.



What are the sizes of the diagnosed, drug-treatable, and/or drug-treated populations?



What is the market outlook of sales and patient share for the next 10 years?



What is the current treatment landscape?



What are the drivers and constraints of market growth, and what events will most impact the market's trajectory?



What products are in development, and what is their launch potential and future positioning?



What unmet needs and opportunities exist?

# Report coverage

## Geography



United States



EU5



Japan

## Market forecast

**Forecast:** Annualized, drug-level sales and patient shares of key ovarian cancer therapies from 2024-2034, segmented by brands / generics.

**Epidemiology:** Total, diagnosed, and drug-treated prevalent cases of ovarian cancer by country.

**Segmentations:** Early-stage, advanced-stage first-line, second-line platinum-sensitive, second-line platinum-resistant and -refractory, third-line platinum-sensitive, third-line platinum-resistant and -refractory, and fourth to sixth lines.

## Primary market research

- Interviews with thought-leading medical oncologists across the G7.
- Data and insights leveraged from 211 physician surveys conducted by Clarivate in ovarian cancer to model current and future market dynamics.

## Key therapies covered

### Marketed therapies / regimens

Bevacizumab (Avastin)

Olaparib (Lynparza)

Rucaparib (Rubraca)

Niraparib (Zejula)

Mirvetuximab soravtansine (Elahere)

Trametinib (Mekinist)

Avutometinib + defactinib (Avmapki Fakzynja Co-pack)

### Emerging therapies / regimens

Raludotatug deruxtecan (Daiichi Sankyo), Phase 3

Pembrolizumab (Merck & Co.), Phase 3

Relacorilant (Corcept Therapeutics), Phase 3


Rinatabart sesutecan (Genmab), Phase 3

Trastuzumab deruxtecan (AstraZeneca / Daiichi Sankyo), Phase 3

Sacituzumab tirumotecan (Merck & Co.), Phase 3

# Report table of contents

1. **Executive Summary**
2. **Key Updates**
3. **Market Forecast**
  - Key takeaways
  - Market drivers and constraints
  - Segment-specific trends
4. **Disease Context**
5. **Epidemiology**
  - Key takeaways
  - Epidemiology populations
    - Diagnosed incident cases
    - Stage distribution of ovarian cancer
    - *BRCA* mutation
    - Recurrent incident cases of ovarian cancer
  - Drug-treatable and drug-treated populations
6. **Current Treatment**
  - Key takeaways
  - Treatment for ovarian cancer
  - Key current therapies
7. **Emerging Therapies**
  - Key takeaways
  - Key emerging therapies
  - Unmet need in ovarian cancer
8. **Drug Pipeline** *(powered by Cortellis)*
9. **Appendix**



## Report format



**In-depth written analyses** available on Clarivate's Insights Platform or as a PDF download



Succinct **Executive Summary** deck



**Market Forecast Assumptions** (flat data file providing comprehensive view of the 10-year, annualized, patient-based market forecast assumptions, including a detailed methodology)




**Market Forecast Dashboard** (interactive tool to help understand, interpret, explore, and visualize key outputs from the market forecast)

# Question answered


What are the expected sales of key drugs used to treat ovarian cancer in the G7 markets over the next 10 years?

| Forecast data by drug                                  |      |      |      |      |      |      |      |      |      |      |      |
|--|------|------|------|------|------|------|------|------|------|------|------|
| Sales (\$M)  |      |      |      |      |      |      |      |      |      |      |      |
|  | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
| Total Ovarian Cancer                                   |      |      |      |      |      |      |      |      |      |      |      |
| Early stage first-line                                 |      |      |      |      |      |      |      |      |      |      |      |
| Advanced stage first-line                              |      |      |      |      |      |      |      |      |      |      |      |
| Second-line platinum-sensitive                         |      |      |      |      |      |      |      |      |      |      |      |
| Second-line platinum-resistant and platinum-refractory |      |      |      |      |      |      |      |      |      |      |      |
| Third-line platinum-sensitive                          |      |      |      |      |      |      |      |      |      |      |      |
| Third-line platinum-resistant and platinum-refractory  |      |      |      |      |      |      |      |      |      |      |      |
| Fourth- to sixth-line                                  |      |      |      |      |      |      |      |      |      |      |      |



# Question answered

What is the current treatment paradigm in ovarian cancer?




# Question answered

When are the key novel therapies expected to launch for the ovarian cancer market over the next 10 years?

| Drug                       | United States | Europe | Japan |
|----------------------------|---------------|--------|-------|
| Pembrolizumab [Keytruda]   | 2026          | 2027   | 2028  |
| Trastuzumab [Herceptin]    |               |        |       |
| Bevacizumab [Avastin]      |               |        |       |
| Carboplatin [Paraplatin]   |               |        |       |
| Paclitaxel [Taxol]         |               |        |       |
| Platinum-based combination |               |        |       |

# Question answered

What clinical unmet needs remain unfulfilled and represent the top opportunities for drug developers?





# About Clarivate

Disease Intelligence and Analytics

# Disease intelligence you can trust



## Size your market

Understand global and local markets, by gauging the size of the drug treatable population, where they're located, and how populations will change over time.



## Identify unmet needs

Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity.



## Fuel successful market access

Optimize your market access strategy with brand-level insight regarding the impact of payer policy on physician prescribing behavior.



## Assess and prioritize opportunities

Evaluate market potential for your assets - and those of your competitors - and optimize your strategy with indication-specific market intelligence combined with world-class epidemiology.



## Understand the patient journey

Gain visibility into brand usage by line of therapy with RWD and uncover the 'why' behind treatment pathways and brand usage with in-depth coverage of physician perceptions on disease management.



## Optimize your brand positioning

Analyze treatment pathways across highly dynamic oncology indications to support brand positioning, strategic planning, and business development.

# Find out more

Learn more about how Clarivate can help you maximize your market share:

[clarivate.com/products/biopharma/portfolio-strategy-business-development](https://clarivate.com/products/biopharma/portfolio-strategy-business-development)



# Think forward™

Contact our experts today:

[lsh.support@clarivate.com](mailto:lsh.support@clarivate.com)

[clarivate.com](https://clarivate.com)

#### About Clarivate

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit [clarivate.com](https://clarivate.com).

© 2025 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.